EP3852718A1 - New compositions comprising oregano extract and uses thereof - Google Patents
New compositions comprising oregano extract and uses thereofInfo
- Publication number
- EP3852718A1 EP3852718A1 EP18773398.5A EP18773398A EP3852718A1 EP 3852718 A1 EP3852718 A1 EP 3852718A1 EP 18773398 A EP18773398 A EP 18773398A EP 3852718 A1 EP3852718 A1 EP 3852718A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- composition according
- present
- amount
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 158
- 240000007673 Origanum vulgare Species 0.000 title claims abstract description 56
- 235000013628 Lantana involucrata Nutrition 0.000 title claims abstract description 55
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 title claims abstract description 55
- 239000000284 extract Substances 0.000 title claims abstract description 42
- 239000003349 gelling agent Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 24
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims description 16
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims description 16
- 235000007746 carvacrol Nutrition 0.000 claims description 14
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims description 14
- 210000002683 foot Anatomy 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 206010017533 Fungal infection Diseases 0.000 claims description 12
- 208000031888 Mycoses Diseases 0.000 claims description 12
- 239000005844 Thymol Substances 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 229960000790 thymol Drugs 0.000 claims description 12
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 11
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 11
- 208000007565 gingivitis Diseases 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 9
- 208000028169 periodontal disease Diseases 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 7
- 229940068968 polysorbate 80 Drugs 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- 201000004647 tinea pedis Diseases 0.000 claims description 7
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 6
- 206010006326 Breath odour Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 208000010195 Onychomycosis Diseases 0.000 claims description 6
- 230000000740 bleeding effect Effects 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 229940055577 oleyl alcohol Drugs 0.000 claims description 6
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 6
- 201000005882 tinea unguium Diseases 0.000 claims description 6
- -1 y-terpinene Chemical compound 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 208000001840 Dandruff Diseases 0.000 claims description 5
- 206010018785 Gingival infections Diseases 0.000 claims description 5
- 208000000112 Myalgia Diseases 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 208000002925 dental caries Diseases 0.000 claims description 5
- 208000013465 muscle pain Diseases 0.000 claims description 5
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- GAIBLDCXCZKKJE-QRYCCKSOSA-N (-)-Germacrene D Natural products C(C)(C)[C@H]1/C=C/C(=C)CC/C=C(/C)\CC1 GAIBLDCXCZKKJE-QRYCCKSOSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- GAIBLDCXCZKKJE-YZJXYJLZSA-N Germacren D Chemical compound CC(C)C/1CC\C(C)=C\CCC(=C)\C=C\1 GAIBLDCXCZKKJE-YZJXYJLZSA-N 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- KMJLGCYDCCCRHH-UHFFFAOYSA-N Spathulenol Natural products CC1(O)CCC2(C)C1C3C(CCC2=C)C3(C)C KMJLGCYDCCCRHH-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical group 0.000 claims description 2
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 claims description 2
- 235000010410 calcium alginate Nutrition 0.000 claims description 2
- 239000000648 calcium alginate Substances 0.000 claims description 2
- 229960002681 calcium alginate Drugs 0.000 claims description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 229940117948 caryophyllene Drugs 0.000 claims description 2
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 claims description 2
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 claims description 2
- FRMCCTDTYSRUBE-HYFYGGESSA-N ent-spathulenol Chemical compound C1CC(=C)[C@H]2CC[C@@](C)(O)[C@@H]2[C@H]2C(C)(C)[C@H]21 FRMCCTDTYSRUBE-HYFYGGESSA-N 0.000 claims description 2
- OJIGFVZZEVQUNV-UHFFFAOYSA-N germacrene D Natural products CC(C)C1CCC=C(/C)CCC(=C)C=C1 OJIGFVZZEVQUNV-UHFFFAOYSA-N 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- GAIBLDCXCZKKJE-UHFFFAOYSA-N isogermacrene D Natural products CC(C)C1CCC(C)=CCCC(=C)C=C1 GAIBLDCXCZKKJE-UHFFFAOYSA-N 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000010408 potassium alginate Nutrition 0.000 claims description 2
- 239000000737 potassium alginate Substances 0.000 claims description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229940116411 terpineol Drugs 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 claims 2
- 230000002500 effect on skin Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 12
- 210000000282 nail Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 238000004817 gas chromatography Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 238000001256 steam distillation Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 5
- 230000003444 anaesthetic effect Effects 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 229940041616 menthol Drugs 0.000 description 5
- 239000010661 oregano oil Substances 0.000 description 5
- 239000006150 trypticase soy agar Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 4
- 229940111617 oregano oil Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 208000024693 gingival disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 3
- IOAISUCAQCEHTA-UHFFFAOYSA-N 5-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=CC=C(C)C=C1O.CC(C)C1=CC=C(C)C=C1O IOAISUCAQCEHTA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 2
- IAIHUHQCLTYTSF-WEDXCCLWSA-N (1r,3r,4s)-2,2,4-trimethylbicyclo[2.2.1]heptan-3-ol Chemical compound C1C[C@]2(C)[C@@H](O)C(C)(C)[C@H]1C2 IAIHUHQCLTYTSF-WEDXCCLWSA-N 0.000 description 1
- GAIBLDCXCZKKJE-BZXLUOIMSA-N (1z,6z)-1-methyl-5-methylidene-8-propan-2-ylcyclodeca-1,6-diene Chemical compound CC(C)C\1CC\C(C)=C/CCC(=C)\C=C/1 GAIBLDCXCZKKJE-BZXLUOIMSA-N 0.000 description 1
- RLXAQIXESOWNGY-UHFFFAOYSA-N 1-methyl-4-propan-2-ylbenzene Chemical compound CC(C)C1=CC=C(C)C=C1.CC(C)C1=CC=C(C)C=C1 RLXAQIXESOWNGY-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 240000004373 Origanum onites Species 0.000 description 1
- 235000000003 Origanum onites Nutrition 0.000 description 1
- 235000010677 Origanum vulgare Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- the present invention relates to stable compositions, such as gel compositions, comprising oregano extract. It also relates to their use as a medicament and in methods of treatment for indications including oral and dermal diseases.
- Periodontal disease commonly known as gum disease
- gum disease is a group of inflammatory diseases affecting the tissues surround the teeth. Good oral hygiene is vital for avoiding gum disease. When oral hygiene is neglected, plaque containing harmful bacteria may build-up on the teeth. This may lead to the early stages of periodontal disease known as gingivitis. During gingivitis, inflammation of the gums renders the gums prone to bleeding, such as during brushing of the teeth.
- gingivitis may progress to a more serious form of gum disease known as periodontitis. This may result in the gums pulling away from the teeth leading to teeth loosening or even falling out. Bad breath may also result.
- Periodontal disease and its symptoms may be prevented and treated by killing or inhibiting the growth of the bacteria responsible.
- Fungal infections of the feet arise from the growth of fungi on the skin and nails of the feet. They generally begin between the toes and move towards the soles and nails of the feet. Two common fungal infections that affect the feet are athlete’s foot and onychomycosis.
- Athlete’s foot also called tinea pedis, commonly affects athletes due to the build-up of heat and sweat in the socks and shoes that occurs during exercise. This creates an ideal environment for the growth of fungus. Athlete’s foot may cause peeling, redness, itching, burning, unpleasant odors, blisters, and sores.
- Onychomycosis is a fungal infection of the nail. It may affect fingernails, but it is more common in toenails because of the moist, warm environment that may arise in the shoes and socks. Onychomycosis may cause the nails to turn grey or yellow, become hard such that they break easily, and cause unpleasant odours.
- Foot fungal infections may be treated by killing or inhibiting the growth of the fungi growing on the feet.
- Oregano may refer to the leaves and flowers separated from the stems of Origanum onites L. or Origanum vulgare L. subsp. Hirtum (Link) letsw. or a mixture of both species. It is a herb which has been used in traditional medicine for many years. Oregano oils, extracted from the dried leaves, are known to demonstrate antibacterial, antifungal, anti-inflammatory and/or antioxidant activity.
- This activity arises from pharmaceutically active compounds present in the extract such as the major phenolic components carvacrol (2-methyl-5-(1 - methylethyl)phenol) and thymol (2-isopropyl-5-methylphenol).
- Oregano and oregano extracts are therefore useful for a variety of medicinal applications in which such activity is beneficial.
- oregano and oregano extracts readily degrade, such as by undergoing oxidation when exposed to air or light, and therefore their stability during storage may be poor making them less suitable as therapeutic compounds.
- the present invention provides a composition comprising a gelling agent and an oregano extract.
- the present invention provides the composition according to the first embodiment for use as a medicament.
- the present invention provides the composition according to the first embodiment for use in the treatment of gingivitis, bleeding gums, periodontal disease, gum infections, bad breath, sensitive teeth, inflammation, tooth decay, acne, dandruff, muscle pain, or fungal infections of the nail or foot, wherein the composition is administered topically or orally.
- the present invention provides a method of treatment of gingivitis, bleeding gums, periodontal disease, gum infections, bad breath, sensitive teeth, inflammation, tooth decay, acne, dandruff, muscle pain, or fungal infections of the nail or foot, which comprises administering to a subject suffering such disease an effective amount of the composition according to the first embodiment, wherein the composition is administered topically or orally.
- the present invention is directed to compositions comprising an oregano extract which may demonstrate excellent stability for long periods of time under typical storage conditions, and to their use as a medicament.
- the composition of the present invention is a pharmaceutical composition.
- the compositions of the present invention comprise an oregano extract.
- the oregano extract may be obtained by any method known to those skilled in the art.
- the oregano extract is obtained via a solvent extraction method.
- the dried leaves of oregano may be processed, i.e. by cutting and crushing the leaves, and then mixed with a solvent to remove the active compounds and form the oregano extract.
- Any suitable solvent may be used such as water, alcohols, such as methanol, ethanol, esters, such as ethyl acetate, and methyl acetate, acetone, hydrocarbons, such as hexane, and petroleum ether, and mixtures thereof.
- the solvent is water, such as purified water which may have been filtered and/or deionised.
- the extraction may be carried out at any temperature such as ambient temperature, for instance from about 10°C to about 35°C, or an increased temperature, such as from about 50°C to about 200°C, preferably from about 80°C to about 150°C.
- the solvent extraction process may be carried out for any suitable time period, such as from about 1 minute to about 24 hours or longer, such as from about 30 minutes to about 10 hours, preferably from about 1 hour to about 6 hours.
- the oregano extract is obtained via a process of steam distillation.
- the steam distillation may be carried out using a vertical condenser or a horizontal condenser. In both cases is it preferable to use a ratio of water to oregano leaves of from about 1 kg to about 50 kg of water, such as from about 5 kg to about 30 kg of water, preferably from about 10 kg to about 20 kg of water, most preferably from about 12 kg to about 15 kg of water, to about 1 kg of oregano leaves.
- steam distillation using a vertical condenser is carried out at a temperature of from about 100°C to about 200°C, such as from about 130°C to about 170°C, preferably from about 140°C to about 150°C.
- the steam distillation process is carried out for from about 1 minute to about 24 hours, such as from about 1 hour to about 10 hours, preferably from about 5 hours to about 6 hours.
- the temperature is typically from about 100°C to about 150°C, such as from about 105°C to about 120°C, preferably from about 1 10°C to about 120°C.
- the steam distillation process is carried out for from about 1 minute to about 24 hours, such as from about 30 minutes to about 5 hours, preferably from about 1 hour to about 3 hours.
- Example 6 it is preferable that a horizontal condenser is used for steam distillation in view of the reduced temperature requirement and lower distillation time.
- the oregano extract comprises one or more compounds present in oregano leaves.
- the skilled person knows the types of compounds that may be extracted from oregano, and the diseases and conditions that they may be used to treat.
- the oregano extract comprises at least one of carvacrol (2-methyl-5-(1 -methylethyl)phenol), thymol (2-isopropyl-5-methylphenol), p-cymene (1 -Methyl-4-(propan-2- yl)benzene), g-terpinene (4-Methyl-1 -(1 -methylethyl)-1 ,4-cyclohexadiene), caryophyllene ((1 R,4E,9S)-4,11 ,1 1 -Trimethyl-8 methylidenebicyclo[7.2.0]undec- 4-ene), spathulenol ((1 aR,4aR,7S,7aR,7bR
- Carvacrol is typically present in the oregano extract in an amount of from about 50% to about 95% by weight, such as from about 70% to about 85% by weight, preferably from about 75% to about 80% by weight, compared to the total weight of the oregano extract.
- Thymol is typically present in the oregano extract in an amount of from about 0.10% to about 2.00% by weight, such as from about 0.20% to about 1.00% by weight, preferably from about 0.40% to about 0.60% by weight, compared to the total weight of the oregano extract.
- the presence and amounts of such compounds in the oregano extract may be determined by any suitable analytical technique, such as gas chromatography (GC). Such techniques are as disclosed in European Pharmacopoeia 9.0 (see pages 1464 to 1466).
- the oregano extract may be present in the composition of the invention in any suitable amount, such as an amount to provide a therapeutic effect.
- the oregano extract may be present in an amount from about 0.01 % to about 10%, preferably from about 0.1 % to about 5%, more preferably from about 0.1 % to about 3%, even more preferably from about 0.1 % to about 1 %, and most preferably from about 0.2% to about 0.6% by weight of the composition.
- the composition of the present invention comprises a gelling agent.
- gelling agent means a substance capable of forming a gel or acting as a thickener, for instance in the composition, thereby increasing the viscosity of the composition.
- Preferable viscosities are from about 3000 to about 6000 cP (centipoise), such as from about 4000 to about 5000 cP, most preferably from about 4490 to about 4500 cP.
- the viscosity may, however, depend upon the intended use.
- the gelling agent may contribute to obtaining the required consistency of the composition, to retaining the physical characteristics of the composition, and to ensuring uniform distribution of the oregano extract in the composition.
- the gelling agent may increase the stability of the formulation, the oregano extract, and/or one or more active compounds, such as those mentioned above, in the oregano extract.
- the improved stability may be with respect to oxidation in air and/or light of the compounds in the oregano extract.
- the gelling agent may be selected from alginic acid, sodium alginate, potassium alginate, calcium alginate, polyvinylpyrrolidone, pectin, starch, carrageenan, locust bean gum, xanthan gum, acacia gum, tragamayth, bentonite, a carbomer, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, and mixtures thereof.
- the gelling agent is a type of cellulose, such as hydroxyethyl cellulose.
- the gelling agent may be present in the composition in any suitable amount, such as an amount that forms a gel.
- the gelling agent may be present in an amount of from about 0.1 % to about 10%, more preferably from about 1 % to about 5%, and most preferably from about 2% to about 4% by weight of the composition.
- a particular feature of the first aspect of the invention is that the gelling agent is hydroxyethyl cellulose which is present in an amount from about 2% to about 4% by weight of the composition.
- composition of the present invention may comprise one or more additional components, such as solvents, surfactants, a source of fluoride, and other pharmaceutically acceptable excipients.
- composition of the present invention may comprise one or more solvents.
- the solvents may be helpful in dissolving one or more components in the composition and in achieving the required consistency of the composition.
- the composition may comprise a solvent selected from propylene glycol, glycerol, water, and mixtures thereof.
- a solvent selected from propylene glycol, glycerol, water, and mixtures thereof.
- the composition comprises propylene glycol.
- the solvent may comprise propylene glycol.
- propylene glycol may be in the composition in an amount of from about 1 % to about 40%, more preferably from about 10% to about 30%, even more preferably from about 15% to about 25%, most preferably from about 18% to about 22% by weight of the composition.
- the composition may comprise glycerol. When present, glycerol may be in the composition in an amount of from about 1 % to about 40%, more preferably from about 10% to about 30%, even more preferably from about 15% to about 25%, most preferably from about 18% to about 22% by weight of the composition.
- the composition may comprise water.
- water may be in the composition in an amount of from about 30% to about 70%, more preferably from about 40% to about 60%, even more preferably from about 45% to about 55%, most preferably from about 50% to about 52% by weight of the composition.
- the composition comprises propylene glycol, glycerol, and water each of which may be present in the amounts defined above.
- composition of the invention may comprise a surfactant.
- Oregano extracts may be immiscible with water.
- the surfactant may help in mixing the oregano extract and water and thereby ensuring a uniform distribution of oregano extract in the composition.
- the surfactant may be anionic, non-ionic, or cationic. They may be a non-ionic surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, oleyl alcohol, and mixtures thereof.
- a particular feature of the first aspect of the invention is that the surfactant is selected from polysorbate 80, oleyl alcohol, or a mixture thereof.
- the surfactant may be present in the composition in any suitable amount. It may be present in an amount from about 0.1 % to about 5%, preferably from about 1 % to 3% by weight of the composition.
- the surfactant comprises polysorbate 80, oleyl alcohol, or a mixture thereof, and present in an amount from about 1 % to about 3% by weight of the composition.
- a source of fluoride may be included in the composition. Fluoride may be used in order to prevent the formation of cavities in the teeth, and may therefore be particularly useful when the composition is for oral administration.
- the source of fluoride may be sodium fluoride.
- the source of fluoride, and in particular sodium fluoride may be present in the composition in any suitable amount. It may be present in an amount of from about 0.01 % to about 1 %, preferably from about 0.1 % to about 0.5%, and most preferably from about 0.2% to about 0.3% by weight of the composition.
- the composition of the present invention may comprise an analgesic or anaesthetic, such as menthol.
- the particular analgesic or anaesthetic used may be dependent upon the intended application of the composition.
- the analgesic or anaesthetic may be used to provide pain relief.
- the analgesic or anaesthetic, such as menthol may be present in any suitable amount such as from about 0.01 % to about 0.1 %, preferably from about 0.02% to about 0.08%, most preferably from about 0.04% to about 0.06% by weight of the composition.
- Menthol may also be included as a skin-penetration enhancer and/or to provide a cooling sensation which may occur due to its ability to dilate blood vessels. In this case, it may be present in the composition in the amounts described above in relation to the amount of analgesic or anaesthetic.
- the composition of the present invention comprises an oregano extract, hydroxyethyl cellulose, propylene glycol, glycerol, and water.
- the oregano extract is present in an amount of from about 0.2% to about 0.6% by weight of the composition
- hydroxyethyl cellulose is present in an amount from about 2% to about 4% by weight of the composition
- propylene glycol is present in an amount from about 18% to about 22% by weight of the composition
- glycerol is present in an amount from about 18% to about 22% by weight of the composition
- water is present in an amount from about 50% to about 52% by weight of the composition.
- the composition of the present invention may have antibacterial, antifungal, anti-inflammatory and/or antioxidant properties. Therefore, the composition of the present invention may be particularly useful as a medicament.
- the composition of the present invention may be useful for the treatment of a range of diseases and conditions, for instance oral diseases and conditions, such as gingivitis, bleeding gums, periodontal disease, gum infections, bad breath, sensitive teeth, inflammation, and tooth decay, skin conditions, such as acne, and dandruff, and other diseases and conditions, such as muscle pain, and fungal infections of the nail or foot such as tinea pedis or onychomycosis.
- oral diseases and conditions such as gingivitis, bleeding gums, periodontal disease, gum infections, bad breath, sensitive teeth, inflammation, and tooth decay, skin conditions, such as acne, and dandruff, and other diseases and conditions, such as muscle pain, and fungal infections of the nail or foot such as tinea pedis or onychomycosis.
- composition may be suitable for topical and/or oral administration to a subject.
- the subject is a mammal, and most preferably a human.
- the composition of the present invention may be administered to any area of the oral cavity, as required. Preferably, it is applied as a thin layer along both sides of the gum.
- composition of the present invention When the composition of the present invention is to be administered topically, it may be administered to any part of the body, as required. For instance, it may be applied as a thin layer to the foot or nail. Again, the skilled person will understand the frequency that the composition may be applied to, or by, a subject, however, it is preferable that the composition is applied twice-a- day after cleaning the affected area, such as with water and subsequent drying.
- composition of the present invention may be stored in airtight container, such as metal tubes, and kept in a cool dark place to help protect the composition against decomposing or degrading.
- airtight container such as metal tubes
- a composition of the present invention was prepared by mixing the components listed in Table 1 as follows. First Phase: Menthol was dissolved in propylene glycol in a main tank. The mixture is visually inspected to confirm that it has dissolved.
- Second Phase Glycerin was added to the main tank and the resulting mixture was mixed for 10 minutes.
- Polysorbate 80 was then added to the main tank. The mixture was then mixed with a homogenizer (Silverson) at a low speed for 10 minutes.
- a homogenizer Silicone
- Example 2 A composition of the present invention was prepared by mixing the components listed in Table 2 as follows.
- Menthol was dissolved in propylene glycol in a main tank. The mixture is visually inspected to confirm that it has dissolved.
- Second Phase Glycerin was added to the main tank and the resulting mixture was mixed for 10 minutes.
- Polysorbate 80 was then added to the main tank. The mixture was then mixed with a homogenizer (Silverson) at a low speed for 10 minutes.
- a homogenizer Silicone
- Example 3 Approximately 15 g of the compositions of Example 1 and Example 2 were each subjected to stability studies under the following storage conditions:
- the concentration of carvacrol and thymol in the composition was determined by gas chromatography (GC) at testing points of 1 month, 2 months, 3 months, and 6 months.
- P is the potency (%) of carvacrol reference standard (e.g. 99.00%) or of thymol reference standard (e.g. 99.50%). Their concentration specification limits is not less than 0.05% of thymol and carvacrol (together).
- the concentration of carvacrol and thymol in the composition was determined by gas chromatography (GC) at testing points of 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, and 36 months.
- the concentrations (%) of carvacrol and thymol in the gel were separately determined by GC method as mentioned above.
- Mouth swab samples were taken from 14 people suffering from gingivitis. The swabs were then transferred into Ringers solution. 1 ml_ of said Ringers solution was transferred to a trypticase soy agar (TSA) plate in order to create a control plate. 1 ml_ of said Ringers solution was transferred to another TSA plate along with 1 g of the composition of Example 1 in order to create a test plate. The control and test plates were incubated for five days at 30 to 35 °C.
- TSA trypticase soy agar
- Example 5 As may be seen from Table 3, the test plate, which included the composition of the present invention, showed a greatly reduced concentration of microorganisms compared to the control plate which did not include the composition of the invention. Therefore, it may be concluded that the composition of Example 1 demonstrates antibacterial activity against bacteria causing gingivitis.
- Example 5
- Foot and nail swab samples were taken from 14 people suffering from a fungal infection.
- the swabs were then transferred into Ringers solution.
- 1 ml_ of said Ringers solution was transferred to a TSA plate in order to create a control plate.
- 1 ml_ of said Ringers solution was transferred to another TSA plate along with 1 g of the composition of Example 2 in order to create a test plate.
- the control and test plates were incubated for five days at 30 to 35 °C.
- Example 2 demonstrates antifungal activity.
- Example 6 formation of an oregano extract Steam distillation was performed in a 50 L reactor using either a vertical condenser or a horizontal condenser. The following examples were carried out multiple times.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2018/075037 WO2020057718A1 (en) | 2018-09-17 | 2018-09-17 | New compositions comprising oregano extract and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3852718A1 true EP3852718A1 (en) | 2021-07-28 |
Family
ID=63667896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18773398.5A Withdrawn EP3852718A1 (en) | 2018-09-17 | 2018-09-17 | New compositions comprising oregano extract and uses thereof |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3852718A1 (en) |
WO (1) | WO2020057718A1 (en) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5756416A (en) * | 1980-09-20 | 1982-04-05 | Lion Corp | Composition for oral cavity |
JPH08175946A (en) * | 1994-12-26 | 1996-07-09 | Kao Corp | Composition for oral composition |
GB9917729D0 (en) * | 1999-07-28 | 1999-09-29 | Boots Co Plc | Hair care composition |
JP2001220337A (en) * | 2000-02-08 | 2001-08-14 | Lion Corp | Composition for oral cavity |
US7829067B2 (en) * | 2004-03-03 | 2010-11-09 | Bio-Botanica, Inc. | Method and composition for treating oral bacteria and inflammation |
US8119169B2 (en) * | 2004-12-28 | 2012-02-21 | Colgate-Palmolive Company | Oregano oral care compositions and methods of use thereof |
EP2007210A4 (en) * | 2006-02-10 | 2011-07-06 | Dupont Tate & Lyle Bio Products Company Llc | Compositions comprising mono and di esters of biologically-based 1.3-propanediol |
US20080020061A1 (en) * | 2006-07-21 | 2008-01-24 | Hassler Mark A | Therapeutic cream |
US8333981B2 (en) * | 2007-10-09 | 2012-12-18 | Humco Holding Group, Inc. | Antifungal treatment of nails |
CN103493849A (en) * | 2013-08-27 | 2014-01-08 | 利辛县永强精炼油脂厂 | Rose essential oil disinfection gel |
MX2015003375A (en) * | 2015-03-17 | 2016-09-16 | Gbs Global S A De C V | Topical composition containing a mixture of synergic plants of the mexican desert as a bioactive organic antifungal, obtaining process and its use against skin mycosis. |
KR101770377B1 (en) * | 2015-07-27 | 2017-09-05 | (주)스킨러버스코스메틱 | Cosmetic composition for improving skin acne and mask pack using the same |
CN105411978A (en) * | 2015-12-15 | 2016-03-23 | 北京健旭康技术有限公司 | Chinese festival cosmetics and manufacturing technology thereof |
CN107296767A (en) * | 2017-07-18 | 2017-10-27 | 佛山市聚成生化技术研发有限公司 | A kind of antibacterial face cream |
-
2018
- 2018-09-17 EP EP18773398.5A patent/EP3852718A1/en not_active Withdrawn
- 2018-09-17 WO PCT/EP2018/075037 patent/WO2020057718A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020057718A1 (en) | 2020-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI106923B (en) | Use of trimethylglycine in preparations for hygiene and care of the mucous membranes of the body | |
EP2155222B1 (en) | Extract of trigonella foenum-graecum | |
JP6077527B2 (en) | Antifungal composition for the treatment of skin and nails | |
EP2814317B1 (en) | Antifungal compositions for use in treatment of a skin disease | |
JP3884808B2 (en) | Oral composition | |
CN105963237B (en) | A kind of Novel mouthwash and its preparation method and application | |
US8383166B2 (en) | Stable hydrophobic topical herbal formulationn | |
JP2000191542A (en) | Preventive/therapeutic agent for osteoporosis | |
RU2313356C1 (en) | Preparation "demalan-aktiv" for demodecosis treatment | |
EP3852718A1 (en) | New compositions comprising oregano extract and uses thereof | |
US20170020946A1 (en) | Analgesic compositions and methods of use | |
Rani et al. | Ethnomedicinal, Pharmacological and Phytochemical Screening of Supari (Areca catechu Linn.): A Review | |
CN113925907A (en) | Antibacterial anti-inflammatory and antiallergic composition as well as preparation method and application thereof | |
JPS63179812A (en) | External preparation for skin | |
JP2018052836A (en) | External composition | |
EP2709606B1 (en) | Compositions containing resveratrol and essential oil of cloves for the treatment of itching | |
US20240269150A1 (en) | Wound treatment composition | |
EP4346760A1 (en) | Composition comprising cannabidiol for application in a body cavity | |
Chaurasiya et al. | OFLOXACIN POLYHERBAL TOPICAL GEL | |
TR2021007003A2 (en) | AN ANTIVIRAL AND ANTIBACTERIAL EFFECTIVE LAVENDER, CEDAR, CITRONELLA, MINT, PALMAROSA, Clove, CYPRESS AND LEMON ESSENTIAL OILS FOR NASAL AND ORAL USE. | |
WO2022082277A1 (en) | Propolis-based natural composition and preparation method | |
JP3304329B2 (en) | Novel antifungal crude organisms active against broad-spectrum dermatophytosis | |
JPH1017484A (en) | Therapeutic agent for fungal and trichophytic dermal and mucosal infectious disease | |
Kriplania et al. | Arnica montana L.–a plant of healing | |
FR2758086A1 (en) | Use of shogaols and gingerols |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210415 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AGETIS SUPPLEMENTS LIMITED |
|
RAV | Requested validation state of the european patent: fee paid |
Extension state: MD Effective date: 20210415 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40058260 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231207 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20240403 |